Grodner C, Sbidian E, Weill A, Mezzarobba M
Département de Dermatologie, AP-HP, Hôpitaux Universitaires Henri Mondor, UPEC, Créteil, France.
GIS-EPIPHARE, Groupement d'intérêt scientifique Epidémiologie des produits de santé ANSM-CNAM, Paris, France.
J Eur Acad Dermatol Venereol. 2021 Feb;35(2):411-416. doi: 10.1111/jdv.16566. Epub 2020 Jun 9.
Psoriasis is one of the most frequent chronic inflammatory dermatoses in the world. Data on the prevalence of psoriasis in adults differ depending on the study.
To estimate the prevalence of patients with treatment for psoriasis in France and to identify and characterize patients receiving systemic treatments.
This was a French, nationwide cohort study based on health administrative data from the French national health insurance scheme linked to the national hospital discharge database (SNDS-PMSI). All adults with psoriasis registered in the SNDS between 1 January 2008 and 31 December 2016 were eligible for inclusion. All patients with a new prescription for a systemic treatment for psoriasis were included.
A total of 874 549 patients were identified as having psoriasis (mean ± SD age 53.8 ± 17 years; 52.4% males); 112 969 (13%) had filled at least one prescription for a systemic medication used to treat psoriasis. The prevalence of patients with treatment for psoriasis was estimated at 1.3%. Overall, 73 168 and 16 545 were new users of conventional systemic treatments and biologics, respectively. The most frequent comorbidities associated with psoriasis were hypertension, dyslipidaemia, diabetes and chronic obstructive pulmonary disease.
The prevalence of psoriasis we found was lower than in other studies. It was probably underestimated because we identified only patients with treatment for psoriasis. Our results concerning comorbidities associated with psoriasis patients requiring systemic treatment were similar to those from other published studies using other data sources, highlighting our ability to catch moderate-to-severe psoriasis. This study highlights the usefulness and reliability of the use of insurance databases in studies, because they allow for a better application to the general population.
银屑病是全球最常见的慢性炎症性皮肤病之一。不同研究中关于成人银屑病患病率的数据有所不同。
评估法国接受银屑病治疗患者的患病率，并识别和描述接受全身治疗的患者。
这是一项基于法国国家健康保险计划的健康管理数据与国家医院出院数据库（SNDS-PMSI）相链接的法国全国性队列研究。2008年1月1日至2016年12月31日期间在SNDS中登记的所有成年银屑病患者均符合纳入条件。纳入所有有银屑病全身治疗新处方的患者。
共识别出874549例银屑病患者（平均±标准差年龄53.8±17岁；男性占52.4%）；112969例（13%）至少开具过一张用于治疗银屑病的全身用药处方。估计接受银屑病治疗患者的患病率为1.3%。总体而言，分别有73168例和16545例是传统全身治疗和生物制剂的新使用者。与银屑病相关的最常见合并症为高血压、血脂异常、糖尿病和慢性阻塞性肺疾病。
我们发现的银屑病患病率低于其他研究。可能被低估了，因为我们仅识别了接受银屑病治疗的患者。我们关于需要全身治疗的银屑病患者合并症的结果与其他使用其他数据源的已发表研究相似，突出了我们捕捉中度至重度银屑病的能力。本研究强调了在研究中使用保险数据库的实用性和可靠性，因为它们能更好地应用于一般人群。
